Remepy Publishes New Evidence Showing its Hybrid Drug, HybridopaTM, Effect on Structural Connectivity in the Brain of Parkinson’s Patients Associated with Improved Clinical Outcome
These findings further strengthen the mechanistic and translational rationale of Hybridopa™ and support its progression toward a Phase III clinical trial
July 1, 2026